AstraZeneca bounces back from scandal in China
Pharma group has installed new leadership in the country and pledged $2.5bn for a Beijing R&D centre
Related reading
AstraZeneca strikes $4.7bn China deal to boost weight-loss drugs pipeline
Drugmaker expands push into fast-growing market
AstraZeneca revives Cambridge investment after UK agrees to pay more for drugs
Resumption of £300mn in UK projects is a result of trade deal with US that aims to increase medicines spending
Britain is squeezing AstraZeneca too tight
NHS curbs on drug prices have alienated UK pharma companies and become self-defeating
AstraZeneca wins shareholder approval for New York listing
Move by FTSE’s biggest company gains support of 99% of shareholders who voted in blow to London market
Europe is risking ‘health sovereignty’ by underpaying for drugs, says…
CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere
Chinese drugmakers shift from copycats to global innovators
Reforms, faster development and lower costs have turbocharged growth